1. Home
  2. CRDL vs VGI Comparison

CRDL vs VGI Comparison

Compare CRDL & VGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

N/A

Current Price

$1.03

Market Cap

97.3M

Sector

Health Care

ML Signal

N/A

Logo Virtus Global Multi-Sector Income Fund of Beneficial Interest

VGI

Virtus Global Multi-Sector Income Fund of Beneficial Interest

N/A

Current Price

$7.33

Market Cap

89.0M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CRDL
VGI
Founded
2017
2012
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
97.3M
89.0M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
CRDL
VGI
Price
$1.03
$7.33
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$9.00
N/A
AVG Volume (30 Days)
365.5K
45.4K
Earning Date
05-13-2026
01-01-0001
Dividend Yield
N/A
12.66%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$7.00
52 Week High
$1.59
$8.09

Technical Indicators

Market Signals
Indicator
CRDL
VGI
Relative Strength Index (RSI) 51.67 26.46
Support Level $0.95 N/A
Resistance Level $1.09 $7.97
Average True Range (ATR) 0.06 0.09
MACD -0.00 -0.03
Stochastic Oscillator 63.00 12.78

Price Performance

Historical Comparison
CRDL
VGI

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest

Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.

Share on Social Networks: